Aravindhan Veerapandiyan, MD, Associate
Professor of Pediatrics, University of
Arkansas for Medical Sciences and Arkansas Children's
Hospital and EXPLORE44® trial investigator, will
present topline del-zota data from Phase 1/2
EXPLORE44 trial at 2025 MDA Clinical & Scientific
Conference in Dallas,
Texas
Avidity to host investor and analyst webcast
event March 17, 2025, at 8:00 a.m. ET
Key opinion leaders to participate in Avidity
sponsored industry forum event "Advancing RNA Therapeutics",
March 17, 2025, at 7:00 a.m. CT/8:00 a.m.
ET
SAN
DIEGO, March 12, 2025 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the company will be presenting one oral and two poster
presentations at the 2025 MDA Clinical & Scientific Conference
(MDA) in Dallas, Texas, being held
March 16-19, 2025 and will host an
investor and analyst webcast event on March
17, 2025.
2025 MDA Clinical & Scientific Conference Oral
& Poster Presentations
March 19, 2025: 9:00 a.m. – 9:15 a.m. CT
- Del-zota produced statistically significant increases in
exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study
in patients with DMD44 (oral presentation)
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics,
University of Arkansas for Medical
Sciences and Arkansas Children's Hospital, and
EXPLORE44® trial investigator, will present topline
del-zota data from Avidity's Phase 1/2 EXPLORE44 trial for people
living with Duchenne Muscular Dystrophy amenable to exon 44
skipping (DMD44).
March 16-18, 2025: 6:00 p.m. – 8:00 p.m. CT
- Del-zota produced statistically significant increases in
exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study
in patients with DMD44 (poster presentation)
- Phase 3, randomized, global study assessing efficacy and
safety of del-desiran for the treatment of myotonic dystrophy
type 1: HARBOR™ trial design (poster presentation)
The presentation and posters will be available on the
publications page of Avidity's website at
https://www.aviditybiosciences.com following the conference.
Avidity Sponsored Industry Forum Breakfast Event During MDA
Conference
On March 17, 2025, 7:00 a.m. CT, Mike
Flanagan, PhD, Chief Scientific Officer at Avidity, will
host an industry forum breakfast titled "Advancing RNA
Therapeutics: Exploring Antibody Oligonucleotide Conjugates (AOCs)
for Rare Neuromuscular Diseases." Dr. Flanagan will be joined
by guest speaker, Nicholas E.
Johnson, MD, MSCI, FAAN, Vice Chair for Research, Department
of Neurology, Virginia Commonwealth
University, and will also be joined by Jeffrey M. Statland, MD, Professor of Neurology,
University of Kansas Medical Center,
and Johanna Hamel, MD, Associate
Professor of Neurology, Psychology and Laboratory Medicine,
University of Rochester to take part in
a Q&A session. Participation will be open to all MDA Conference
registered attendees.
Avidity Investor and Analyst Webcast
Avidity management will be joined by Kevin Flanigan, MD, Robert F. and
Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular
Research at Nationwide
Children's Hospital, and Professor
of Pediatrics and Neurology at the Ohio State University College of
Medicine, on March 17,
2025, at 8:00 a.m. ET for a
live video webcast to discuss del-zota topline data from the
EXPLORE44 trial, which will be available on the
company's website at
https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity is
revolutionizing the field of RNA with its proprietary AOCs, which
are designed to combine the specificity of monoclonal antibodies
with the precision of oligonucleotide therapies to address targets
and diseases previously unreachable with existing RNA therapies.
Utilizing its proprietary AOC platform, Avidity demonstrated the
first-ever successful targeted delivery of RNA into muscle and is
leading the field with clinical development programs for three rare
muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular
dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and immunology
through internal discovery efforts and key partnerships. Avidity is
headquartered in San Diego, CA. For more information about our AOC
platform, clinical development pipeline and people, please
visit www.aviditybiosciences.com and engage with us
on LinkedIn and X.
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
Media Contact:
(619) 837-5016
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical--scientific-conference-302400330.html
SOURCE Avidity Biosciences, Inc.
